<< AHF schedules safer sex awareness events to mark International Condom Day on Feb 13th | Trimel BioPharma Holdings updates business developments >>
Read in | English | Español

Report on market potential for RNA therapies

Published on February 10, 2010 at 9:28 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/e45ece/ribonucleic_acid) has announced the addition of the "Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma" report to their offering.

“Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma”

Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma provides insights into the unmet needs in the pharmaceutical and healthcare market and potential segments where RNA therapies can prove to be useful. This pharma report also delves deep into the market potential that RNA therapies hold in the future. Further, it provides insights into the R&D pipeline and the promising drugs. The study elucidates the current competitive landscape of the RNA therapeutics market. Finally, the report deals with key trend analysis on mergers and acquisitions, and licensing agreements involving RNA therapies.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Scope

The scope of this report includes:

  • Detailed market characterization including evaluation of market potential, annual cost of therapy and treatment usage patterns
  • Key technologies that have created significant impact on research and development of RNA therapeutics
  • Key factors that can drive the RNA therapeutics market potential
  • Key risks and issues associated with various RNA therapies
  • Competitive landscape of RNA therapeutics market. The key companies studied in this report are Antisense Pharma GmbH, Lorus Therapeutics, Isis Pharmaceuticals, Alfacell Corporation, Genta Incorporated, Atlantic Healthcare, Alnylam, OPKO, Oxford BioMedica, Dicerna Pharmaceuticals, Silence Therapeutics plc, Cequent Pharmaceuticals, Inc and Santaris Pharma.
  • Key M&A activities and licensing agreements that have taken place between 2008 and 2009 in the RNA therapeutics market.

Reasons to buy

The report will aid business development and marketing executives in strategizing their product launches and help venture capitalists to identify promising small and medium sized enterprises. It will allow you to

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading